PMID- 10578457
OWN - NLM
STAT- MEDLINE
DCOM- 19991229
LR  - 20220408
IS  - 0006-3223 (Print)
IS  - 0006-3223 (Linking)
VI  - 46
IP  - 10
DP  - 1999 Nov 15
TI  - Olanzapine safety and efficacy in patients with borderline personality disorder 
      and comorbid dysthymia.
PG  - 1429-35
AB  - BACKGROUND: Numerous medications have been tested in patients with borderline 
      personality disorder (BPD) and/or schizotypal personality disorder (SPD). 
      Although many of the medications tested have been demonstrated to be useful, no 
      clear main treatment for BPD has emerged. Despite the efficacy of some of the 
      medicines, acceptability and side effects have proven to be barriers to the use 
      of medication. Therefore, an open-label olanzapine trial utilizing objective 
      ratings was performed. METHODS: Patients suffering from BPD and dysthymia were 
      included in an 8-week, open-label study of olanzapine monotherapy. The first 4 
      weeks of the trial allowed for flexible dosing; during the last 4 weeks, 
      olanzapine dose was held constant. Patients were rated on Hopkins Symptoms 
      Checklist 90 (SCL-90), Brief Psychiatric Rating Scale (BPRS), Global Assessment 
      of Function (GAF), Barratt Impulsivity Scale (BIS 11), and Buss-Durkee Hostility 
      Inventory (BDHI). RESULTS: Eleven patients completed at least 2 weeks; nine of 
      the patients finished the entire trial. There was a robust and statistically 
      significant reduction in the five global ratings. Within the global ratings, 
      symptoms of psychoticism, depression, interpersonal sensitivity, and anger were 
      among the symptoms to be reduced. No movement disorder symptoms were noted for 
      any of the patients. CONCLUSIONS: In this open-label pilot study, patients 
      treated with olanzapine showed statistically significant reduction in self-rated 
      and clinician-rated scales. Symptoms associated with BPD and dysthymia were among 
      those to be substantially reduced. Further studies to explore olanzapine's 
      efficacy versus placebo, as well as comparison to other potential treatments for 
      BPD, are important next steps.
FAU - Schulz, S C
AU  - Schulz SC
AD  - Department of Psychiatry, University of Minnesota Medical School, Minneapolis 
      55454-1495, USA.
FAU - Camlin, K L
AU  - Camlin KL
FAU - Berry, S A
AU  - Berry SA
FAU - Jesberger, J A
AU  - Jesberger JA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biol Psychiatry
JT  - Biological psychiatry
JID - 0213264
RN  - 0 (Antipsychotic Agents)
RN  - 12794-10-4 (Benzodiazepines)
RN  - 3G0285N20N (Pirenzepine)
RN  - N7U69T4SZR (Olanzapine)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/*therapeutic use
MH  - Benzodiazepines
MH  - Borderline Personality Disorder/*complications/diagnosis/*drug therapy
MH  - Brief Psychiatric Rating Scale
MH  - *Consumer Product Safety
MH  - Dose-Response Relationship, Drug
MH  - Dysthymic Disorder/*complications/diagnosis
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Olanzapine
MH  - Pirenzepine/*analogs & derivatives/therapeutic use
MH  - Severity of Illness Index
EDAT- 1999/12/01 00:00
MHDA- 1999/12/01 00:01
CRDT- 1999/12/01 00:00
PHST- 1999/12/01 00:00 [pubmed]
PHST- 1999/12/01 00:01 [medline]
PHST- 1999/12/01 00:00 [entrez]
AID - S0006-3223(99)00128-6 [pii]
AID - 10.1016/s0006-3223(99)00128-6 [doi]
PST - ppublish
SO  - Biol Psychiatry. 1999 Nov 15;46(10):1429-35. doi: 10.1016/s0006-3223(99)00128-6.